Cynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women's health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
Phone+1-978-2564200
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Cynosure (NASDAQ:CYNO) Frequently Asked Questions
What is Cynosure's stock symbol?
Cynosure trades on the NASDAQ under the ticker symbol "CYNO."
How were Cynosure's earnings last quarter?
Cynosure, Inc. (NASDAQ:CYNO) released its quarterly earnings data on Tuesday, July, 26th. The medical equipment provider reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.07. The medical equipment provider earned $110.30 million during the quarter, compared to analyst estimates of $101.31 million. The business's quarterly revenue was up 31.8% compared to the same quarter last year. During the same period last year, the business earned $0.30 earnings per share. View Cynosure's Earnings History.
Has Cynosure been receiving favorable news coverage?
Media coverage about CYNO stock has been trending somewhat positive this week, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cynosure earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned media headlines about the medical equipment provider a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the near term.
What other stocks do shareholders of Cynosure own?
How do I buy shares of Cynosure?
Shares of CYNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cynosure's official website?
How can I contact Cynosure?
Cynosure's mailing address is 5 Carlisle Rd, WESTFORD, MA 01886-3601, United States. The medical equipment provider can be reached via phone at +1-978-2564200.
MarketBeat Community Rating for Cynosure (NASDAQ CYNO)
MarketBeat's community ratings are surveys of what our community members think about Cynosure and other stocks. Vote "Outperform" if you believe CYNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYNO will underperform the S&P 500 over the long term. You may vote once every thirty days.
